Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® (APL-1702) subject to certain conditions, Advancing the Global Development and Commercialization of a First-in-Class Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

SHANGHAI, China and LONDON, UK — Oct 7. 2026 — Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative therapies for the treatment of genitourinary tumors and gynecological diseases, and Theramex, a global specialty pharmaceutical company dedicated to women and their health, today announced that they have entered into an […] The post Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® (APL-1702) subject to certain conditions, Advancing the Global Development and Commercializatio